Condition: Newly Diagnosed Multiple Myeloma · Sponsor: PETHEMA Foundation
This is a Phase III open-label, 3-arm, parallel, randomized, controlled trial. The allocation ratio 1:1:1 and outcome assessment are blind to group allocation. Patients will be randomized from 3 arms. Patients will receive VRD extended + ASCT plus ERI or Isatuximab-VRD + ASCT or Isatuximab-VID + ASCT.
This description comes directly from the study's public registry record.
Carmen López-Carrero · 0034 699 835 437 · carmen@fundacionpethema.es
Roberto Maldonado · 0034 683 15 66 87 · roberto.maldonado@fundacionpethema.es
Always discuss trial participation with your own doctor first.
| Hospital Principe de Asturias | Alcalá de Henares, Madrid, Spain | Recruiting |
| Hospital Universitario Quirón Salud Madrid | Pozuelo de Alarcón, Madrid, Spain | Recruiting |
| Clinica Universidad Navarra (CUN) | Pamplona, Navarre, Spain | Recruiting |
| Hospital General Universitario de Albacete | Albacete, Spain | Recruiting |
| Hospital Germans Trias i Pujol (ICO BADALONA) | Badalona, Spain | Recruiting |
| Hospital Clinic i Provincial de Barcelona | Barcelona, Spain | Recruiting |
| Hospital de la Santa Creu i Sant Pau | Barcelona, Spain | Recruiting |
| Hospital Universitari Vall d´Hebron | Barcelona, Spain | Recruiting |
| ICO L´Hospitalet | Barcelona, Spain | Recruiting |
| Hospital Universitario de Cruces | Bilbao, Spain | Recruiting |
| Hospital Universitario de Burgos | Burgos, Spain | Recruiting |
| Complejo Hospitalario de Cáceres | Cáceres, Spain | Recruiting |
+ 56 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05558319